AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript
AstraZeneca Plc (NASDAQ: AZN) Q3 2024 Earnings Call Nov 12, 2024, 9:00 a.m. ET ...
AstraZeneca reports Q3 core EPS $2.08, consensus $1.03
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
Benzinga.com2d
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
Yahoo Finance2d
AstraZeneca’s 9M and Q3 2024 results
Additionally, the quality and impact of our scientific research was well recognised this quarter with data for AstraZeneca medicines featuring in an unprecedented five Presidential Plenary sessions ...
The Washington Post2d
Astrazeneca: Q3 Earnings Snapshot
CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...
AstraZeneca Q3 Earnings Preview: Will Cancer, Heart Drugs Fuel Continued Growth?
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...
devdiscourse1d
Pharma Updates: Amgen Overcomes Concerns, AstraZeneca Expands, and Pfizer Considers Sale
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...